1. <li id="pwivh"></li>
      2. <th id="pwivh"></th>
        <button id="pwivh"></button>

        <button id="pwivh"><acronym id="pwivh"></acronym></button>

        <del id="pwivh"><bdo id="pwivh"><em id="pwivh"></em></bdo></del>
        <em id="pwivh"></em><tbody id="pwivh"><noscript id="pwivh"></noscript></tbody>
      3. <dd id="pwivh"><noscript id="pwivh"></noscript></dd>

          1. <rp id="pwivh"><object id="pwivh"><input id="pwivh"></input></object></rp>
            <span id="pwivh"></span>
            <rp id="pwivh"><acronym id="pwivh"><input id="pwivh"></input></acronym></rp>
             
             
             
             
             
            專職PI
            胡欣 研究員
            研究員,博士
            E-mail: xinhu.nlorg@gmail.com
             

              2008年從癌基因及相關基因國家重點實驗室(上海市腫瘤研究所)獲復旦大學博士學位。2009至2012年在美國德州大學M.D.安德森癌癥中心分子遺傳系從事博士后研究。2012年進入復旦大學附屬腫瘤醫院/腫瘤研究所工作,現為研究員,碩士生導師;擔任精準腫瘤中心副主任、腫瘤研究所所長助理、上海市乳腺腫瘤重點實驗室秘書等職務。主要從事乳腺癌腫瘤基因組學、腫瘤耐藥機制研究、DNA損傷和修復以及高通量文庫篩選方向的研究,主要研究成果發表在Cancer Cell, Cell Research, Nature Commun, Hepatology, Cancer Res, JBC 等國際期刊。獲得上海市青年科技“啟明星”、復旦大學附屬腫瘤醫院“優秀碩士生導師”、“十大醫務青年”稱號。


            研究領域:

              1.乳腺癌腫瘤基因組學;
              2.腫瘤耐藥機制研究;
              3.DNA損傷修復研究;
              4.高通量文庫篩選。


            代表性論著:

            1. Wang D#, Hu X#, Liu C, Jia Y, Bai Y, Cai C, Wang J, Bai L, Yang R, Lin C, Liu YR, Li S, Qiao F, Yao L, Chen L, Ge G, Jiang H, Li D, Li L, Chen J, Shao ZM*, Zeng YA*. Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers. Cell Res, 2019 Sep 3. (IF= 17.848)
            2. Jiang YZ#, Ma D#, Suo C#, Shi J#, Xue M#, Hu X#, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P*, Shi L*, Huang W*, Shao ZM*. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 2019 Mar 18; 35(3):428-440.e5 (IF= 22.844)
            3. Liu Y#, Xue M#, Du S, Feng W, Zhang K, Zhang L, Liu H, Jia G, Wu L, Hu X*, Chen L*, Wang P*. Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT. Nat Commun,2019 Apr 9; 10(1):1637. (IF=12.124)
            4. Chen L#, Yang L#, Yao L#, Kuang XY, Zuo WJ, Li S, Qiao F, Liu YR, Cao ZG, Zhou SL, Zhou XY, Yang WT, Shi JX, Huang W, Hu X*, Shao ZM*. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun, 2018 Apr 10; 9(1):1357. (IF=12.124)
            5. Zheng YZ, Xue MZ, Shen HJ, Li XG, Ma D, Gong Y, Liu YR, Qiao F, Xie HY, Lian B, Sun WL, Zhao HY, Yao L, Zuo WJ, Li DQ, Wang P, Hu X*, Shao ZM*. PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression. Cancer Res, 2018 Jun 15; 78(12):3190-3206 (IF= 9.122)
            6. Ye FG#, Song CG#*, Cao ZG, Xia C, Chen DN, Chen L, Li S, Qiao F, Ling H, Yao L, Hu X*, Shao ZM. Cytidine deaminase axis modulated by miR-484 differentially regulates cell proliferation and chemoresistance in breast cancer. Cancer Res, 2015 Apr 1; 75(7):1504-15. (IF= 9.122)
            7. Kuang XY#, Jiang HS#, Li K, Zheng YZ, Liu YR, Qiao F, Li S, Hu X*, Shao ZM*. The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis. Cancer Lett, 2016 Jul 0; 377(1):87-96. (F1000)(IF= 6.375)
            8. Hu X#, Zhao Y#, He X, Li J, Wang T, Zhou W, Wan D, Wang H, Gu J*. Ciliary neurotrophic factor receptor alpha subunit-modulated multiple downstream signaling pathways in hepatic cancer cell lines and their biological implications. Hepatology, 2008 Apr; 47(4):1298-308. (IF= 11.36)
            9. Hu X, Paul A, Wang B. Rap80 Protein Recruitment to DNA Double-strand Breaks Requires Binding to Both Small Ubiquitin-like Modifier (SUMO) and Ubiquitin Conjugates. J Biol Chem, 2012 Jul 20; 287(30):25510-9. (IF= 4.77)
            10. Hu X, Kim J, Castillo A, Huang M, Liu J, Wang B*. NBA1/Merit40 and BRE interaction is required for the integrity of two distinct deubiqutinating enzyme BRCC36 containing complexes. J Biol Chem2011 Apr 1; 286(13):11734-45. (IF=4.77) F1000
             
            復旦大學腫瘤研究所 通訊地址: 東安路270號2號樓1312室 64175590-5312 Email:fuci2012@126.com
            Copyright 2013 shca.org.cn All rights reserved. 復旦大學腫瘤研究所 版權所有
            最新国模无码国产在线视频 <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>